Market Cap | 3.01B | P/E | - | EPS this Y | - | Ern Qtrly Grth | 7.30% |
Income | -50M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -10.00% |
Sales | 947M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 2.00% |
Dividend | N/A | Price/Book | 41.85 | EPS next 5Y | - | 52W High Chg | -71.00% |
Recommedations | - | Quick Ratio | 0.91 | Shares Outstanding | 137.88M | 52W Low Chg | 48.00% |
Insider Own | - | ROA | 8.23% | Shares Float | 112.34M | Beta | -0.06 |
Inst Own | 0.08% | ROE | -32.90% | Shares Shorted/Prior | -/- | Price | 21.85 |
Gross Margin | 83.00% | Profit Margin | -5.28% | Avg. Volume | 3,566 | Target Price | - |
Oper. Margin | 24.18% | Earnings Date | - | Volume | 8,103 | Change | 0.00% |
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Jefferies | Hold | Nov 21, 18 |